NUVLHealthcare · BiotechnologyNUVL Stock Forecast: Nuvalent, Inc. Price Predictions for 2026-2027
The 9 Wall Street analysts covering Nuvalent, Inc. hold a median 12-month price target of $124 — +0.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 55 of 100 as at 15 July 2026 — in the upper half.
NUVL stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Nuvalent, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (97): The shares have been drifting up relative to others.
Growth (32): Sales and profits are flat, shrinking, or growing more slowly than they were.
Size (16): Larger than most of the companies we track — more scrutinised, less often mispriced.
The rank is the raw material. Whether the rules would actually own Nuvalent, Inc. — and when they’d sell — is the membership.
NUVL stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on NUVL, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
The green dot is the last close — the median target sits +0.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 24 June 2026 | Bernstein | Downgrade | Market Perform | $172 → $124 |
| 24 June 2026 | Bernstein | Downgrade | Market Perform | — |
| 10 June 2026 | Barclays | Downgrade | Equal-Weight | — |
| 10 June 2026 | Guggenheim | Downgrade | Neutral | — |
| 10 June 2026 | TD Cowen | Downgrade | Hold | — |
| 10 June 2026 | Truist Securities | Downgrade | Hold | — |
| 10 June 2026 | UBS | Downgrade | Neutral | — |
| 10 June 2026 | Wedbush | Downgrade | Neutral | — |
| 9 June 2026 | Cantor Fitzgerald | Downgrade | Neutral | — |
| 9 June 2026 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 9 June 2026 | LifeSci Capital | Downgrade | Market Perform | — |
| 9 June 2026 | Wedbush | Downgrade | Neutral | — |
| 9 June 2026 | Wells Fargo | Downgrade | Equal-Weight | — |
| 28 May 2026 | Wedbush | Reiterates | Outperform | — |
| 22 May 2026 | Bernstein | Initiates | Outperform | — |
| 21 Apr 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 8 Apr 2026 | Wedbush | Reiterates | Outperform | — |
| 30 Mar 2026 | Wells Fargo | Initiates | Overweight | — |
| 27 Feb 2026 | Cantor Fitzgerald | Maintains | Overweight | — |
| 19 Dec 2025 | JP Morgan | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
NUVL analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Nuvalent, Inc. (NUVL) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −21.2×
- Price / sales
- —
- Price / book
- 8.3×
- EV / EBITDA
- −20.5×
Cheaper than 96% of US stocks
Cheaper than 12% of US stocks
Cheaper than 89% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −41.2%
- Return on assets
- −22.5%
- Dividend yield
- —
Higher than 23% of US stocks
Higher than 18% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
NUVL vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NUVL appears on the weeks it earns a place.
Frequently asked questions about NUVL stock
What is the NUVL stock price forecast for 2026-2027?
The 9 Wall Street analysts covering Nuvalent, Inc. have a median 12-month price target of $124, with estimates ranging from $124 to $124. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is NUVL stock a buy right now?
Of the 9 analysts covering Nuvalent, Inc., 0 rate it a Buy, 9 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Nuvalent, Inc. 55 out of 100 across roughly 4,600 US stocks as at 15 July 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank NUVL?
As at 15 July 2026, Nuvalent, Inc. ranks 55 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (97 of 100).
Will NUVL stock go up?
No one can know that. What the data says: the median 12-month target from 9 analysts implies +0.0% from the last close, and Ticker Nerd's factor model ranks Nuvalent, Inc. 55 out of 100 as at 15 July 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the NUVL stock forecast for 2030?
No analyst covering Nuvalent, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NUVL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $124 to $124 over the next 12 months.
What does Nuvalent, Inc. do?
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on developing precisely targeted therapies for patients with cancer.
About Nuvalent, Inc.
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on developing precisely targeted therapies for patients with cancer. The company applies structure-based drug design and chemistry expertise to create small-molecule treatments aimed at clinically proven kinase targets, with an emphasis on improving selectivity and addressing resistance mechanisms. Its current programs center on non-small cell lung cancer, including therapies for ROS1-positive and ALK-positive disease, as well as a HER2-altered program in early clinical development. Nuvalent’s work is positioned within the oncology sector, where it contributes to the development of targeted medicines intended to support more durable responses and better tolerability across patient populations.
CEO Dr. James R. Porter Ph.D. · 234 employees · United States · https://nuvalent.com